{"filing":{"accession_number":"0001193125-26-381060","cik":"0001768446","ticker":"CLYM","company_name":"Climb Bio, Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"d97033d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526381060/d97033d8k.htm"},"events":[{"id":31477,"run_id":28884,"accession_number":"0001193125-26-381060","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Climb Bio disclosed positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody, including a ~29-day half-life, \u003e90% APRIL suppression, and favorable safety profile supporting every-12-week dosing. This is a material clinical development milestone for a lead pipeline asset, but does not constitute an earnings release (no financial results), M\u0026A activity, or other specifically-defined event type. The disclosure is clearly operational—a significant clinical program update—rather than financial, governance, or legal in nature.","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34372,"accession_number":"0001193125-26-381060","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Climb Bio disclosed positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody, including a ~29-day half-life, \u003e90% APRIL suppression, and favorable safety profile supporting every-12-week dosing. This is a material clinical development milestone for a lead pipeline asset, but does not constitute an earnings release (no financial results), M\u0026A activity, or other specifically-defined event type. The disclosure is clearly operational—a significant clinical program update—rather than financial, governance, or legal in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T11:52:57.657740+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34372,"accession_number":"0001193125-26-381060","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Climb Bio disclosed positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody, including a ~29-day half-life, \u003e90% APRIL suppression, and favorable safety profile supporting every-12-week dosing. This is a material clinical development milestone for a lead pipeline asset, but does not constitute an earnings release (no financial results), M\u0026A activity, or other specifically-defined event type. The disclosure is clearly operational—a significant clinical program update—rather than financial, governance, or legal in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T11:52:57.657740+00:00","company_name":"Climb Bio, Inc.","ticker":"CLYM","filing_date":"2026-09-03"}]}